Valuation: Beximco Pharmaceuticals PLC.

Market Cap 63.39B 510M 455M 418M 380M 712M 48.27B 727M 4.99B 2.01B 25.48B 1.91B 1.87B 80.47B P/E 2026
6.97x
P/E 2027 * 6.39x
Enterprise Value 63.39B 510M 455M 418M 380M 712M 48.27B 727M 4.99B 2.01B 25.48B 1.91B 1.87B 80.47B EV / Sales 2026
-
EV / Sales 2027 * 1.03x
Free-Float
85.91%
Yield 2026 *
4.24%
Yield 2027 * 4.85%
1 day-1.52%
1 week-2.67%
Current month-1.11%
1 month-3.46%
3 months-5.83%
6 months+23.78%
Current year+39.18%
1 week 141.7
Extreme 141.7
145.8
1 month 138.5
Extreme 138.5
147.9
Current year 99.5
Extreme 99.5
158.5
1 year 99.5
Extreme 99.5
158.5
3 years 64.2
Extreme 64.2
158.5
5 years 64.2
Extreme 64.2
234
10 years 47.36
Extreme 47.363636
255.4
Manager TitleAgeSince
Chief Executive Officer - 04/03/2024
Director of Finance/CFO 63 01/01/2003
Chief Administrative Officer - -
Director TitleAgeSince
Chairman - 19/06/2009
Director/Board Member - 01/02/2010
Director/Board Member - 01/01/1985
Change 5-day change 1-year change 3-year change Capi.($)
-1.52%-2.67%+21.66%-2.80% 519M
-0.46%+10.80%+63.52%+154.48% 1,263B
-0.97%+2.56%+43.25%+81.96% 658B
-2.05%+1.12%+32.47%+102.74% 521B
-1.54%+1.61%+53.42%+67.10% 391B
-0.78%+2.13%+72.55%+44.25% 369B
-1.69%+2.75%+32.49%+54.35% 307B
-0.72%+8.08%+11.15%+34.09% 290B
-0.12%+5.96%+55.97%+78.44% 252B
-0.21%+9.16%+42.19%+112.41% 212B
Average -0.69%+5.26%+42.87%+72.70% 426.24B
Weighted average by Cap. -0.45%+6.60%+49.14%+97.41%

Financials

2026 *2027 *
Net sales 54.78B 441M 393M 361M 328M 616M 41.71B 628M 4.31B 1.74B 22.02B 1.65B 1.62B 69.54B 61.27B 493M 440M 404M 367M 689M 46.65B 702M 4.82B 1.94B 24.62B 1.85B 1.81B 77.77B
Net income 8.66B 69.66M 62.2M 57.07M 51.92M 97.34M 6.6B 99.28M 682M 275M 3.48B 261M 256M 10.99B 9.92B 79.77M 71.22M 65.36M 59.45M 111M 7.55B 114M 781M 315M 3.99B 299M 293M 12.59B
Net Debt - -
Projected Income Statement - Annual - Beximco Pharmaceuticals PLC.
Logo Beximco Pharmaceuticals PLC.
Beximco Pharmaceuticals Plc, formerly Beximco Pharmaceuticals Limited, is a Bangladesh-based manufacturer and exporter of medicines. The Company manufactures generic pharmaceutical products and active pharmaceutical ingredients (APIs). It offers products in diverse therapeutic categories, which include antibiotics, analgesics, anti-diabetic, respiratory, cardiovascular, central nervous system, dermatology, and gastrointestinal. Its portfolio of generics encompasses diverse delivery systems such as tablets, capsules, liquids, semi-solids, intravenous fluids, metered dose inhalers, dry powder inhalers, sterile ophthalmic drops, insulins, prefilled syringes, injectables, nebuliser solutions, oral soluble films, and others. The Company also undertakes contract manufacturing for multinational and global generic pharmaceutical companies. Its allergic disorders include Atrizin, Axodin, Bexidal, Curin, Duvent, Momento, and others. Its cardiovascular includes Amdocal, Amdocal Plus, and others.
Employees
1,223
Date Price Change Volume
02/11/26 BDT 142.10 -1.52% 386,700
01/11/26 BDT 144.30 +0.42% 381,201
29/10/26 BDT 143.70 +0.49% 473,934
28/10/26 BDT 143.00 +0.14% 312,831
27/10/26 BDT 142.80 -1.24% 700,170
Trader
Investor
-
Global
-
Quality
ESG MSCI
-
MarketScreener Ratings - Beximco Pharmaceuticals PLC.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
142.10BDT
Average target price
198.55BDT
Spread / Average Target
+39.73%

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Beximco Pharmaceuticals PLC.
  1. Stock Market
  2. Stocks
  3. BXPHARMA Stock